Clinical trials: Advanced Malignant Solid Tumours
Unresectable or Metastatic Advanced Solid Tumors
A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors
This trial is a multi-center, open-label investigator-initiated clinical study (IIT) to evaluate the safety, pharmacokinetics, pharmacodynamics and effectiveness of WTX212A injection in the treatment of patients with unresectable…
- Trial name
- NCT06026605
- Testing
- WTX212A
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Zhejiang University
Malignant Solid Tumour
ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
The purpose of the study is to investigate the safety and the recommended dose for later use of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the treatment of advanced cancers.
- Trial name
- NCT01598129
- Testing
- ONCOS-102
- Where
- Finland
- Volunteers
- 12 people
- Sponsor
- Targovax Oy
Advanced Solid Tumors
A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors
An Open-label, Single-arm, Phase I Clinical Study of GK01 Cell Injection in the Treatment of Patients with Advanced Malignant Solid Tumors
- Trial name
- NCT07482319
- Testing
- GK01 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Neoplasms
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
This dose-escalating study consists of 3 parts (A, B and C) and will evaluate the safety, pharmacokinetics and efficacy of RO5479599, alone or in combination with cetuximab or erlotinib, in participants with metastatic and/or…
- Trial name
- NCT01482377
- Testing
- RO5479599, Cetuximab, Erlotinib
- Where
- 12 sites in Denmark, Netherlands and 2 more
- Volunteers
- 145 people
- Sponsor
- Hoffmann-La Roche
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00066651
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer, Cancer (Solid Tumors)
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT07317505
- Testing
- JMT108
- Where
- 3 sites in United States
- Volunteers
- 270 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
SMMART Adaptive Clinical Treatment (ACT) Trial
SMMART-ACT is a feasibility pilot study to determine if testing samples from a participant's cancer using a precision medicine approach can be used to identify specific drugs or drug combinations that can help control their…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT05238831
- Testing
- Alectinib, Alpelisib, Anastrozole
- Sponsor
- OHSU Knight Cancer Institute
Solid Cancer, Haematological Malignancies
Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)
This is an open-label, single-centre, category 2 "Jardé Law" proof-of-concept study designed to demonstrate the feasibility of a decentralised care pathway for patients with cancer or haematological malignancies receiving oral…
- Trial name
- NCT06797037
- Testing
- Decentralised Pathway Coordinated by the Advanced Practice Nurse
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Institut Claudius Regaud
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Studying TAK-243 in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT06223542
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
This trial investigates the experience and satisfaction of care in patients with cancer that has spread to other places in the body (advanced) and their caregivers living in underserved areas of Kenya, Nigeria, Ghana, South…
- Trial name
- NCT04984551
- Testing
- Extension of Community Health (ECHO) Telementoring Clinic, In-Country Workshops, Professional Oncology Educations Programs
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Neoplasms, Neoplasm Malignant
AIMS Cancer Outcomes Study
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in…
- Conditions
- Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor
- Trial name
- ACOS (NCT04495790)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Advanced Integrative Medical Science Institute
Cancer, Tumor, Solid
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or…
- Conditions
- Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05082610
- Testing
- HMBD-002, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Hummingbird Bioscience
Solid Tumor Malignancies, Malignant Mesothelioma (MM)
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
- Trial name
- NCT07282873
- Testing
- TYK-01054
- Where
- China
- Volunteers
- 219 people
- Sponsor
- TYK Medicines, Inc
Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
This phase Ib/II trial studies the best dose of glembatumumab vedotin when giving together with nivolumab and ipilimumab in treating patients with solid tumor that has spread to other places in the body and cannot be removed by…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative, GPNMB Positive, HER2/Neu Negative
- Trial name
- NCT03326258
- Testing
- Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumor, Malignant Pleural Effusion
A Study of MT027 in Patients with Pleural Malignant Tumors
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who…
- Conditions
- Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma, Pleural Mesothelioma
- Trial name
- NCT06726564
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose.
- Conditions
- Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer
- Trial name
- LTbR (NCT06448364)
- Testing
- PF-07329640, sasanlimab, bevacizumab
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- Pfizer
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor…
- Trial name
- NCT05819684
- Testing
- SHR-4602 for injection
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.